[4-(Morpholine-4-carbonyl)phenyl]boronic acid → 1-Methylethyl 4-({[4'-(4-morpholinylcarbonyl)-4-biphenylyl]oxy}methyl)-1-piperidinecarboxylate

Participants

Reaction Steps

The title compound (37 mg, 32%) was prepared from [4-(4-morpholinylcarbonyl)phenyl]boronic acid (47 mg, 0.2 mmol) and 1-methylethyl 4-{[(4-bromophenyl)oxy]methyl}-1-piperidinecarboxylate (prepared as in Example 9, Step 2, 71 mg, 0.2 mmol) in a manner similar to Example 21, Step 3, and worked up in a manner similar to Example 9, Step 3. 1H NMR (400 MHz, CDCl3): δ 7.58 (m, 2H) 7.51 (d, 2H, J=8.8 Hz), 7.46 (d, 2H, J=8.2 Hz), 6.96 (d, 2H, J=8.8 Hz), 4.97-4.86 (m, 1H), 4.21 (bs, 2H), 3.85 (d, 2H, J=6.2 Hz), 3.72 (bs, 6H), 3.53 (bs, 2H), 2.84-2.74 (m, 2H), 2.05-1.95 (m, 1H), 1.90-1.80 (m, 2H), 1.36-1.26 (m, 2H), 1.24 (d, 6H, J=6.4 Hz); LRMS (ESI), m/z 467 (M+H).

Provenance & Evidence